



Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES)

EU – H2020 project grant agreement no 634935

Website: bridges-research.eu

Deliverable Number	5.1
Deliverable Title	Survey results of BOADICEA
Short Title	SurveyBOADICEA
Lead beneficiary	IC
Del. Date (Annex 1)	01/09/2017
Achieved Date	16/06/2017
Nature	Report
Dissemination Level	PU
Document Filename	D51-SurveyBOADICEA-PU-v1.0.pdf
DOI Publication	10.1007/s10689-017-0014-x

Abstract

The 'BOADICEA' Web Application (BWA) used to assess breast cancer risk, is currently being further developed, to integrate additional genetic and non-genetic factors. We surveyed clinicians' perceived acceptability of the existing BWA v3. An online survey was conducted through the BOADICEA website, and the British, Dutch, French and Swedish genetics societies. Cross-sectional data from 443 participants who provided at least 50% responses were analysed. This survey results have been reported in a peer-reviewed publication referenced below. It was concluded that further development of BWA should consider technological, genetics service delivery and training initiatives. Additional analyses of this survey address the usage frequencies of the BWA and six other common BC risk assessment tools, and explored their correlates with genetics and oncology health professionals' background and attitudes towards BC risk factors. These results will be available in a publication under preparation.

The full results describing D5.1 "Survey results of BOADICEA" can be found in the following article:

Brédart A, Kop JL, Antoniou AC, Cunningham AP, De Pauw A, Tischkowitz M, Ehrencrona H, Dolbeault S, Robieux L, Rhiem K, Easton DF, Devilee P, Stoppa-Lyonnet D, Schmutzler R. Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries. *Fam Cancer*. 2017 Jun 16. doi:[10.1007/s10689-017-0014-x](https://doi.org/10.1007/s10689-017-0014-x). [Epub ahead of print] PubMed PMID: 28623477

Conclusion: D5.1 has been achieved in time.